Physician profile
Christopher Bird
NPI 1336793454
$1,493.90
in general payments reported to CMS, 2019-2025
12 companies · $832 in 2025
The $832 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $662 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.82 | 2024-2025 | |
| Pfizer INC. | $385.96 | 2024-2025 | |
| Eisai INC. | $143.33 | 2024-2025 | |
| Ucb, INC. | $69.39 | 2024-2025 | Briviact |
| Sk Life Science, INC. | $53.45 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $49.45 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Glaxosmithkline, LLC. | $35.44 | 2025 | Nucala |
| Kyowa Kirin, INC. | $30.68 | 2024 | Nourianz |
| Lundbeck LLC | $27.08 | 2024 | Rexulti |
| Genzyme Corporation | $24.97 | 2024 | |
| Mylan Specialty L.P. | $19.59 | 2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $13.74 | 2024 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.